Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.06 -0.09 (-4.19%) Market Cap: 413.83 Mil Enterprise Value: 369.69 Mil PE Ratio: 0 PB Ratio: 7.09 GF Score: 31/100

Taysha Gene Therapies Inc R&D Day 1 Transcript

Jun 28, 2021 / 02:00PM GMT
Release Date Price: $24.94 (+3.92%)
Unidentified Company Representative

Good morning, and welcome to day 1 of Taysha Gene Therapies First R&D Day. (Operator Instructions) Today, the company will present new data and updates for many of its pipeline candidates. Joining the call today is R.A. Session II, Taysha's President, Founder and Chief Executive Officer; Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; and Dr. Steve Gray, Chief Scientific Adviser and Associate Professor in the Department of Pediatrics at UT Southwestern.

Before we begin, please note that this presentation will include forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see Slide 2 of the accompanying presentation and Taysha's SEC filings for important risk factors that could cause the company's actual performance and results to differ materially from those expressed or implied in these forward-looking statements. Taysha undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot